Haw Par Corporation Limited (HAWPY)
USD 35.95
(7.63%)
USD 35.95
(7.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 70.05 Million SGD | -57.59% |
| 2022 | 165.17 Million SGD | 34.65% |
| 2021 | 122.67 Million SGD | -6.23% |
| 2020 | 130.82 Million SGD | -35.75% |
| 2019 | 85.21 Million SGD | 2.42% |
| 2018 | 89.56 Million SGD | 37.34% |
| 2017 | 77.6 Million SGD | 1.91% |
| 2016 | 78.37 Million SGD | -31.5% |
| 2015 | 60.45 Million SGD | 60.23% |
| 2014 | 50.41 Million SGD | 7.02% |
| 2013 | 44.68 Million SGD | -8.32% |
| 2012 | 132.12 Million SGD | 26.2% |
| 2011 | 91.96 Million SGD | 16.17% |
| 2010 | 128.92 Million SGD | 3.53% |
| 2009 | 86.89 Million SGD | -20.49% |
| 2008 | 93.65 Million SGD | -2.42% |
| 2007 | 112 Million SGD | -7.69% |
| 2006 | 121.34 Million SGD | 23.42% |
| 2005 | 98.31 Million SGD | 32.98% |
| 2004 | 93.01 Million SGD | 4.59% |
| 2003 | 70.69 Million SGD | -7.49% |
| 2002 | 76.41 Million SGD | 23.61% |
| 2001 | 61.81 Million SGD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 17.16 Million SGD | -12.06% |
| 2024 Q2 | 17.16 Million SGD | 0.0% |
| 2023 Q1 | 15.41 Million SGD | 21.59% |
| 2023 Q4 | 19.51 Million SGD | 0.0% |
| 2023 FY | - SGD | -57.59% |
| 2023 Q2 | 15.41 Million SGD | 0.0% |
| 2023 Q3 | 19.51 Million SGD | 26.64% |
| 2022 Q4 | 12.67 Million SGD | 0.0% |
| 2022 FY | - SGD | 34.65% |
| 2022 Q1 | 11.75 Million SGD | -19.76% |
| 2022 Q2 | 23.79 Million SGD | 102.51% |
| 2022 Q3 | 12.67 Million SGD | -46.74% |
| 2021 Q1 | 7.94 Million SGD | 2060.74% |
| 2021 Q4 | 14.64 Million SGD | 91.71% |
| 2021 Q3 | 7.63 Million SGD | -51.05% |
| 2021 Q2 | 15.6 Million SGD | 96.52% |
| 2021 FY | - SGD | -6.23% |
| 2020 Q1 | 11.88 Million SGD | -30.27% |
| 2020 Q3 | -1.64 Million SGD | -107.1% |
| 2020 FY | - SGD | -35.75% |
| 2020 Q4 | -405 Thousand SGD | 75.45% |
| 2020 Q2 | 23.23 Million SGD | 95.51% |
| 2019 FY | - SGD | 2.42% |
| 2019 Q4 | 17.04 Million SGD | -72.72% |
| 2019 Q3 | 62.46 Million SGD | -35.05% |
| 2019 Q2 | 96.18 Million SGD | 244.3% |
| 2019 Q1 | 27.93 Million SGD | 18.51% |
| 2018 Q1 | 25.61 Million SGD | 18.73% |
| 2018 Q4 | 23.57 Million SGD | -62.3% |
| 2018 Q3 | 62.52 Million SGD | -28.22% |
| 2018 Q2 | 87.1 Million SGD | 240.08% |
| 2018 FY | - SGD | 37.34% |
| 2017 FY | - SGD | 1.91% |
| 2017 Q4 | 21.57 Million SGD | -51.65% |
| 2017 Q3 | 44.62 Million SGD | -21.12% |
| 2017 Q2 | 56.56 Million SGD | 157.14% |
| 2017 Q1 | 21.99 Million SGD | -12.95% |
| 2016 Q4 | 25.27 Million SGD | -45.12% |
| 2016 FY | - SGD | -31.5% |
| 2016 Q3 | 46.04 Million SGD | -11.42% |
| 2016 Q2 | 51.98 Million SGD | 177.41% |
| 2016 Q1 | 18.73 Million SGD | -31.74% |
| 2015 FY | - SGD | 60.23% |
| 2015 Q4 | 27.45 Million SGD | -34.96% |
| 2015 Q3 | 42.21 Million SGD | -64.83% |
| 2015 Q2 | 120.02 Million SGD | 579.51% |
| 2015 Q1 | 17.66 Million SGD | -17.02% |
| 2014 Q3 | 26.34 Million SGD | -58.54% |
| 2014 Q4 | 21.28 Million SGD | -19.21% |
| 2014 Q1 | 16.04 Million SGD | -39.75% |
| 2014 FY | - SGD | 7.02% |
| 2014 Q2 | 63.54 Million SGD | 295.98% |
| 2013 Q1 | 11.04 Million SGD | -70.49% |
| 2013 Q3 | 25.61 Million SGD | -54.47% |
| 2013 Q2 | 56.25 Million SGD | 409.57% |
| 2013 FY | - SGD | -8.32% |
| 2013 Q4 | 26.63 Million SGD | 4.0% |
| 2012 Q1 | 9.85 Million SGD | -45.47% |
| 2012 Q3 | 24.03 Million SGD | -49.57% |
| 2012 Q4 | 37.4 Million SGD | 55.62% |
| 2012 FY | - SGD | 26.2% |
| 2012 Q2 | 47.67 Million SGD | 383.72% |
| 2011 Q4 | 18.07 Million SGD | 74.32% |
| 2011 Q1 | 8.82 Million SGD | -23.02% |
| 2011 Q2 | 50.29 Million SGD | 470.01% |
| 2011 FY | - SGD | 16.17% |
| 2011 Q3 | 10.36 Million SGD | -79.39% |
| 2010 Q2 | 44.94 Million SGD | 352.2% |
| 2010 Q4 | 11.46 Million SGD | -51.47% |
| 2010 FY | - SGD | 3.53% |
| 2010 Q3 | 23.61 Million SGD | -47.45% |
| 2010 Q1 | 9.93 Million SGD | 8.71% |
| 2009 Q1 | 10.51 Million SGD | 0.0% |
| 2009 Q4 | 9.14 Million SGD | -62.79% |
| 2009 Q3 | 24.57 Million SGD | -42.41% |
| 2009 Q2 | 42.66 Million SGD | 305.72% |
| 2009 FY | - SGD | -20.49% |
| 2008 FY | - SGD | -2.42% |
| 2007 FY | - SGD | -7.69% |
| 2006 FY | - SGD | 23.42% |
| 2005 FY | - SGD | 32.98% |
| 2004 FY | - SGD | 4.59% |
| 2003 FY | - SGD | -7.49% |
| 2002 FY | - SGD | 23.61% |
| 2002 Q2 | 15.98 Million SGD | 0.0% |
| 2002 Q4 | 17.5 Million SGD | 0.0% |
| 2001 FY | - SGD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | 99.473% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | 99.639% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | 93.898% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 276.449% |
| Novartis AG | 19.51 Billion USD | 99.641% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | 75.685% |